IP Library Granted Patent US 7,655,224
Granted Patent B2
US 7,655,224 · App. 11/546,726 · Granted Feb 2, 2010

Neural stem cells and use thereof for brain tumor therapy

Assignees: Children's Medical Center Corp.; The General Hospital Corp.; Northeastern Ohio Universities COM
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,655,224
App. No.
11/546,726
Granted
Feb 2, 2010
Kind
B2
Abstract

The present invention is based upon a surprising finding that stem cells, more particularly neural stem cells, can migrate throughout a brain tumor and track metastatic brain tumor cells. The invention provides a method for treating brain tumors by administering genetically engineered neural stem cells in an individual affected by brain tumors. The invention also provides a method of preparing genetically engineered neural stem cells and a composition comprising genetically engineered neural stem cells in a pharmaceutically acceptable carrier.

Claims (7)

1. A method of treating a diffuse or metastatic brain tumor in an adult human subject having a diffuse or metastatic brain tumor, said method comprising:

a) providing a plurality of neuronal stem cells comprising a vector encoding a therapeutic agent; and

b) intracranially administering said plurality of neuronal stem cells in a pharmaceutically acceptable carrier into a first location in a non-tumorigenic brain tissue of said adult human subject, wherein said plurality of neuronal stem cells migrate from the first location to a second location containing at least one tumor cell and distant from the first location, to specifically target and surround the at least one tumor cell to deliver the therapeutic agent in the vicinity of said tumor cell, and thereby treating the diffuse or metastatic brain tumor.

2. The method of claim 1 , wherein the diffuse or metastatic brain tumor is a malignant glioma.

3. The method of claim 1 , wherein the vector is deficient for a component necessary for vector replication.

4. The method of claim 3 , wherein the component necessary for vector replication is ribonucleotide reductase.

5. The method of claim 1 , wherein the diffuse or metastatic brain tumor is a cerebral metastasis from an extracerebral tumor.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 23, 2020
From: BOSTON CHILDREN'S HOSPITAL
To: NIH-DEITR
Reel/Frame 053017/0579 →
Continuity (5)
Continuation 0979567500 · Feb 28, 2001
Continuation In Part 0916835000 · Oct 7, 1998
Continuation In Part 0913387300 · Aug 14, 1998
Provisional Application 6018557200 · Feb 28, 2000
Related Publication 20070031391A1 · Feb 8, 2007